Search Result

Results for "

3CL(pro)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (2) Antibiotic (1) Apoptosis (9) Bacterial (4) Cathepsin (3) Cytochrome P450 (5) Endogenous Metabolite (5) Fungal (2) G protein-coupled Bile Acid Receptor 1 (1) HBV (1) HCV (18) HCV Protease (14) HIV (24) HIV Protease (24) HSV (2) Influenza Virus (1) Isotope-Labeled Compounds (13) MMP (3) Opioid Receptor (2) P-glycoprotein (5) PKC (1) PROTACs (1) Ras (1) SARS-CoV (94) Virus Protease (4)
By Research Areas:	Cancer (23) Infection (94) Inflammation/Immunology (6) Metabolic Disease (3) Neurological Disease (2)

By Targets:

Adenosine Receptor (2)

Antibiotic (1)

Apoptosis (9)

Bacterial (4)

Cathepsin (3)

Cytochrome P450 (5)

Endogenous Metabolite (5)

Fungal (2)

G protein-coupled Bile Acid Receptor 1 (1)

HBV (1)

HCV (18)

HCV Protease (14)

HIV (24)

HIV Protease (24)

HSV (2)

Influenza Virus (1)

Isotope-Labeled Compounds (13)

MMP (3)

Opioid Receptor (2)

P-glycoprotein (5)

PKC (1)

PROTACs (1)

Ras (1)

SARS-CoV (94)

Virus Protease (4)

By Research Areas:

Cancer (23)

Infection (94)

Inflammation/Immunology (6)

Metabolic Disease (3)

Neurological Disease (2)

101

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-144833

SARS-CoV-2 3CLpro-IN-1	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-1 (Compound 14c) is a potent inhibitor of SARS-CoV-2 3CL ^pro. 3CL ^pro (main coronaviruses cysteine-protease) has been identified as a promising target for the development of antiviral agents. SARS-CoV-2 3CLpro-IN-1 has the potential for the research of infection diseases .

HY-151535

SARS-CoV-2 3CLpro-IN-5	SARS-CoV	Infection Inflammation/Immunology
SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor of 3C-like protease (3CL ^pro). SARS-CoV-2 3CLpro-IN-5 has inhibitory activity for 3CL ^pro with an IC₅₀ value of 3.8 nM. SARS-CoV-2 3CLpro-IN-5 has 9.0% oral bioavailability (BA). SARS-CoV-2 3CLpro-IN-5 can be used for the research of coronavirus disease 2019 (COVID-19) .

HY-156007

SARS-CoV-2 3CLpro-IN-21	SARS-CoV Virus Protease	Infection
SARS-CoV-2 3CLpro-IN-21 (Compound D6) irreversibly and covalently inhibits SARS-CoV-2 *3CL ^pro* with an IC₅₀ of 0.03 μM. SARS-CoV-2 3CLpro-IN-21 also inhibits SARS-CoV-13CL ^pro with an IC₅₀ of 0.12μM .

HY-152005

SARS-CoV-2 3CLpro-IN-6	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-6 is a reversible covalent inhibitor of SARS-CoV-2 3CL protease. SARS-CoV-2 3CLpro-IN-6 has potent inhibitory activity for SARS-CoV-2 3CL ^pro with an IC₅₀ value of 4.9 μM. SARS-CoV-2 3CLpro-IN-6 can be used for the research of coronavirus disease 2019 (COVID-19) .

HY-162313

NIP-22c	SARS-CoV	Infection
NIP-22c is a novel coronavirus *3CL_pro* inhibitor. The EC₅₀ for Verona, Calu3, Caco2 and HBTEC-ALI were 4.6, 1.1, 0.1 and 0.6 μM, respectively. NIP-22c has antiviral activity .

HY-139311

YH-53	SARS-CoV	Infection
YH-53 is a potent *3CL ^pro* inhibitor with K_i values of 6.3 nM, 34.7 nM for SARS-CoV-1 3CL ^pro and SARS-CoV-2 3CL ^pro, respectively. YH-53 strongly blocks the SARS-CoV-2 replication. YH-53 is a peptidomimetic compound with a unique benzothiazolyl ketone. YH-53 has the potential for COVID-19 research .

HY-149655

D1N8	SARS-CoV	Infection
D1N8 is a potent SARS-CoV-2 3CL ^pro inhibitor with an IC₅₀ and CC₅₀ values of 0.44 μM and >20 μM, respectively. D1N8 has the potential for the research of anti-SARS-CoV-2 agents targeting 3CL ^pro .

HY-144062

INSCoV-614(1B)	SARS-CoV	Infection
INSCoV-614(1B) is a potent inhibitor of M ^pro (3CL ^pro). Proteases (PL ^pro and 3CL ^pro) are involved with transcription and replication of the virus. INSCoV-614(1B) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .

HY-132306

CCF0058981 CCF981	SARS-CoV Virus Protease	Infection
CCF0058981 (CCF981), 3-chlorophenyl analogue, is a noncovalent *SARS-CoV-2 3CL ^pro* (SC2) inhibitor with an IC₅₀** of 68 nM. CCF0058981 inhibits SC1 (SARS-CoV-1 3CL ^pro) with an IC₅₀ of 19 nM. CCF0058981 has antiviral efficacy and has the potential for COVID-19 research .

HY-144061

INSCoV-601I(1)	SARS-CoV	Infection
INSCoV-601I(1) is a potent inhibitor of M ^pro (3CL ^pro). Proteases (PL ^pro and 3CL ^pro) are involved with transcription and replication of the virus. INSCoV-601I(1) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .

HY-144063

INSCoV-600K(1)	SARS-CoV	Infection
INSCoV-600K(1) is a potent inhibitor of M ^pro (3CL ^pro). Proteases (PL ^pro and 3CL ^pro) are involved with transcription and replication of the virus. INSCoV-600K(1) has the potential for the research of SARS-CoV-2 infection (extracted from patent WO2021219089A1) .

HY-149656

D1N52

SARS-CoV Infection

D1N52 is a potent SARS-CoV-2 3CL ^pro inhibitor with an IC₅₀ of 0.53 μM .

D1N52	SARS-CoV	Infection
D1N52 is a potent SARS-CoV-2 3CL ^pro inhibitor with an IC₅₀ of 0.53 μM .

HY-137048

PF-00835231 1 Publications Verification	SARS-CoV	Infection
PF-00835231 is a CoV-2 cysteine 3C-like protease (3CL ^pro) inhibitor, with IC₅₀s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CL ^pro, respectively. PF-00835231 is developed for the research of anti-SARS-CoV-2/COVID-19 sup>[2].

HY-17007

Saquinavir 5+ Cited Publications Ro 31-8959	HIV HIV Protease SARS-CoV	Infection Cancer
Saquinavir(Ro 31-8959) is an HIV Protease inhibitor used in antiretroviral therapy. Saquinavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.36 μM.

HY-90001

Ritonavir 20+ Cited Publications ABT 538; RTV	HIV Protease HIV SARS-CoV Apoptosis	Infection Cancer
Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.61 μM.

HY-155979

SARS-CoV-2 3CLpro-IN-16	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-16 (Compound 3a) is a covalent SARS-CoV-2 3CLpro inhibitor (IC₅₀s: 2.124 μM). SARS-CoV-2 3CLpro-IN-16 binds to the active site and forms a covalent bond with Cys145 of 3CLpro .

HY-152589

Antiviral agent 25	SARS-CoV	Infection
Antiviral agent 25 (compound 6g) is a new non-peptide analog covalent inhibitor of SARS-CoV-2 3CL ^pro. Antiviral agent 25 has a strong inhibitory effect on SARS-CoV-2 3CL ^pro and SARS-CoV-2 PL ^pro with IC₅₀ values of 0.118 µM, 0.448 µM, respectively. Antiviral agent 25 has antiviral effect on SARS-CoV-2 with an EC₅₀ value of 7.249 µM .

HY-17430

Amprenavir 5+ Cited Publications VX-478	HIV HIV Protease SARS-CoV	Infection Cancer
Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.09 μM.

HY-147804

SARS-CoV-2 3CLpro-IN-3	SARS-CoV Bacterial Fungal	Infection
SARS-CoV-2 3CLpro-IN-3 (Compound 3d) is a SARS CoV-2 3CLpro inhibitor with antiviral, antibacterial and antifungal activities .

HY-147805

SARS-CoV-2 3CLpro-IN-4	SARS-CoV Bacterial Fungal	Infection
SARS-CoV-2 3CLpro-IN-4 (Compound 5g) is a SARS CoV-2 3CLpro inhibitor with antiviral, antibacterial and antifungal activities .

HY-155980

SARS-CoV-2 3CLpro-IN-17

SARS-CoV Infection

SARS-CoV-2 3CLpro-IN-17 (Compound 3h) is a selective SARS-CoV-2 3CLpro inhibitor (IC₅₀s: 0.322 μM) .
HY-162414

SARS-CoV-2-IN-84

SARS-CoV Infection

SARS-CoV-2-IN-84 (compound 20) is aSARS-CoV-2 inhibitor that targets the 3CL protease (3CL Pro) of SARS-CoV-2 (IC₅₀: 369.5 nM ). .

SARS-CoV-2 3CLpro-IN-17	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-17 (Compound 3h) is a selective SARS-CoV-2 3CLpro inhibitor (IC₅₀s: 0.322 μM) .

SARS-CoV-2-IN-84	SARS-CoV	Infection
SARS-CoV-2-IN-84 (compound 20) is aSARS-CoV-2 inhibitor that targets the 3CL protease (3CL Pro) of SARS-CoV-2 (IC₅₀: 369.5 nM ). .

HY-155540

SARS-CoV-2 3CLpro-IN-14	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-14 (compound 11j) is an orally active SARS-CoV-2 3CLpro inhibitor. SARS-CoV-2 3CLpro-IN-14 shows significant anti-SARS-CoV-2 activity (EC₅₀ = 0.18 μM) and low cytotoxicity (CC₅₀ > 50 μM) in Vero E6 cells .

HY-W760546

SARS-CoV-2 3CLpro-IN-15	SARS-CoV Virus Protease	Infection
SARS-CoV-2 3CLpro-IN-15 (compound a) is a beta-nitrostyrene coronavirus SARS-CoV-2 inhibitor that targets the SARS-CoV-2 3CL protease (3CLpro). SARS-CoV-2 3CLpro-IN-15 inhibits viral replication and transcription and plays a key role in the discovery of anti-COVID-19 lead compounds .

HY-155187

SARS-CoV-2 3CLpro-IN-20

SARS-CoV Infection

SARS-CoV-2 3CLpro-IN-20 (Compound 5g) is a covalent SARS-CoV-2 3CLpro inhibitor (IC₅₀s: 0.43 μM, K_i: ?0.33?μM) .

SARS-CoV-2 3CLpro-IN-20	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-20 (Compound 5g) is a covalent SARS-CoV-2 3CLpro inhibitor (IC₅₀s: 0.43 μM, K_i: ?0.33?μM) .

HY-155981

SARS-CoV-2 3CLpro-IN-18	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-18 (Compound 3C) is a covalent SARS-CoV-2 3CLpro inhibitor (IC₅₀s: 0.478 μM). SARS-CoV-2 3CLpro-IN-18 inhibits SARS-CoV-2 in Vero E6 cells (EC₅₀= 2.499 μM) with low cytotoxicity (CC₅₀ > 200 μM) .

HY-17634

Glecaprevir 5 Publications Verification ABT-493	HCV HCV Protease SARS-CoV	Infection
Glecaprevir is a novel HCV NS3/4A protease inhibitor, with IC₅₀ values ranging from 3.5 to 11.3 nM. Glecaprevir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 4.09 μM .

HY-161177

PROTAC KRAS G12D degrader 2	PROTACs Ras	Infection
PROTAC KRAS G12D degrades SARS-CoV-2, 3-curd trypsin-like protease (3CLPro). Protac KRAS G12D degrades SARS-CoV-2, 3-curd trypsin-like protease (3CLPRO). The PROTAC molecule is designed by partially coupling a GC-376-based dipeptidyl 3CLPro ligand with pomadomide via a piperazine-piperidine linker .

HY-146998

SARS-CoV-2 3CLpro-IN-2	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-2 (Compound 1) is a potent inhibitor of 3CL protease. SARS-CoV-2 3CLpro-IN-2 has the potential for the research of SARS-CoV-2 diseases .

HY-149264

SARS-CoV-2 3CLpro-IN-13	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-13 is a potent SARS-CoV-2 3CL protease inhibitor with an IC₅₀ value of 21 nM. SARS-CoV-2 3CLpro-IN-13 shows anti-coronavirus activity .

HY-154965

Simnotrelvir SIM0417; SARS-CoV-2-IN-41	SARS-CoV	Infection
SARS-CoV-2-IN-41 (compound 2) is a potent SARS-CoV-2 3CL ^pro inhibitor with an IC₅₀ value of 0.022 µM. SARS-CoV-2-IN-41 shows antiviral effect .

HY-157477

SARS-CoV-2 3CLpro-IN-22	SARS-CoV Cathepsin	Infection
SARS-CoV-2 3CLpro-IN-22 (Compound 17) is a cathepsin L (CTSL ) inhibitor with an IC₅₀ value of 32.5 nM. SARS-CoV-2 3CLpro-IN-22 can be used for the study of SARS-CoV-2 virus .

HY-18219

Walrycin B 1 Publications Verification	SARS-CoV Bacterial Antibiotic	Infection Inflammation/Immunology
Walrycin B, an analogue of toxoflavin, is a potent SARS-CoV-2 3CL ^pro inhibitor with an IC₅₀ of 0.26 μM. Walrycin B is a WalR response regulator inhibitor. Walrycin B has potent activity of inhibiting bacteria growth .

HY-90001R

Ritonavir (Standard) ABT 538 (Standard); RTV (Standard)	HIV Protease HIV SARS-CoV Apoptosis	Infection Cancer
Ritonavir (Standard) is the analytical standard of Ritonavir. This product is intended for research and analytical applications. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.61 μM.

HY-90001S2

Ritonavir-d8 ABT 538-d₈; RTV-d₈	Apoptosis HIV Protease SARS-CoV HIV Isotope-Labeled Compounds	Infection Cancer
Ritonavir-d₈ is deuterated labeled Ritonavir (HY-90001). Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.61 μM.

HY-155186

SARS-CoV-2 3CLpro-IN-19	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-19 (Compound C5a) is a non-covalent, non-peptide SARS-CoV-2 3CLpro inhibitor (IC₅₀s: 0.7 μM). SARS-CoV-2 3CLpro-IN-19 has broad-spectrum activity against Omicron subvariants (BA.5, BQ.1.1, and XBB.1.5) infection in human cells, with EC₅₀ values between 30-69 nM .

HY-157966

SARS-CoV-2 3CLpro-IN-23	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-23 (Compound Cd3) is a compound that can be isolated from Citrus depressa. SARS-CoV-2 3CLpro-IN-23 has good inhibitory activity to the SARS-CoV-2 spike protein, with K_D of 0.79 μM. SARS-CoV-2 3CLpro-IN-23 can bind to key amino acid residue, disrupting the formation of the spike protein and h-ACE2 complex .

HY-14434

Asunaprevir 30+ Cited Publications BMS-650032	HCV HCV Protease SARS-CoV	Infection
Asunaprevir (BMS-650032) is a potent and orally bioavailable hepatitis C virus (HCV) NS3 protease inhibitor, with IC₅₀ of 0.2 nM-3.5 nM . Asunaprevir inhibits SARS-CoV-2 3CL ^pro activity .

HY-144260

3CPLro-IN-1	SARS-CoV	Infection
3CPLro-IN-1 (compound A17) is a potent and orally active inhibitor of SARS-CoV-2 3CLpro with an IC₅₀ of 5.65 μM. 3-Chymotrypsin-like cysteine protease (3CLpro) is an indispensable protein in viral replication and represents an attractive agent target for fighting COVID-19 .

HY-149535

WU-04	SARS-CoV	Infection
WU-04 is a non-covalent inhibitor of SARS-CoV-2, targeting the 3CLpro protein. WU-04 has high inhibitory effect on the 3CLpro protein of 6 SARS-CoV-2 variants (Alpha, Beta, Gamma, Delta, Lambda and Omicron) and 2 coronaviruses (SARS-CoV and MERS-CoV) .

HY-133862

SCH-202676	Influenza Virus G protein-coupled Bile Acid Receptor 1 Adenosine Receptor	Infection
SCH-202676 is an allosteric modulator of G protein-coupled receptors (GPCRs) and adenosine receptor (AR). SCH-202676 has antiviral activity and inhibits 3CL ^pro in a time-dependent manner with an IC₅₀ value of 0.655 µM ^[3] .

HY-138687

Nirmatrelvir Maximum Cited Publications 44 Publications Verification PF-07321332	SARS-CoV	Infection Inflammation/Immunology
Nirmatrelvir (PF-07321332) is a potent and orally active **SARS-CoV 3C-like protease (3CL ^PRO)** inhibitor. Nirmatrelvir (PF-07321332) targets to the SARS-CoV-2 virus and can be used for COVID-19 research .

HY-144263

3CPLro-IN-2	SARS-CoV	Infection
3CPLro-IN-2 (compound C1) is a potent and orally active inhibitor of SARS-CoV-2 3CLpro with an IC₅₀ and K_i of 1.55 and 6.09 μM, respectively. 3-Chymotrypsin-like cysteine protease (3CLpro) is an indispensable protein in viral replication and represents an attractive agent target for fighting COVID-19 .

HY-15602

Ledipasvir 25+ Cited Publications GS-5885	HCV SARS-CoV	Infection
Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC₅₀s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.62 μM ^[3].

HY-15602C

Ledipasvir hydrochloride GS-5885 hydrochloride	HCV SARS-CoV	Infection
Ledipasvir (GS-5885) hydrochloride is an inhibitor of the hepatitis C virus NS5A, with EC₅₀s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir hydrochloride is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.62 μM ^[3].

HY-110012

SCH-202676 hydrobromide	Adenosine Receptor	Infection
SCH-202676 hydrobromide is an allosteric modulator of G protein-coupled receptors (GPCRs) and adenosine receptor (AR). SCH-202676 hydrobromide has antiviral activity and inhibits 3CL ^pro in a time-dependent manner with an IC₅₀ value of 0.655 μM ^[3] .

HY-N12384

(25S)-Antcin B

SARS-CoV Infection

Antcin-B is a potent inhibitor of 3CLPro with high affinity. Antcin-B can be used in study SARS-CoV-2 .

HY-138078

Lufotrelvir 1 Publications Verification PF-07304814	SARS-CoV	Infection
Lufotrelvir (PF-07304814), a phosphate proagent of PF-00835231, acts as a potent 3CLpro protease (Mpro) inhibitor with SARS-CoV-2 antiviral activity. Lufotrelvir binds and inhibits SARS-CoV-2 3CLpro activity with a Ki of 174nM. Lufotrelvir is promising single antiviral agent and also can be used for the research of combination with other antivirals that target other critical stages of the coronavirus life cycle.

HY-136259

ML188 4 Publications Verification	SARS-CoV Virus Protease	Infection
ML188, a first in class probe, is a selective non-covalent SARS-CoV *3CLpro* inhibitor with an IC₅₀ of 1.5 μM. Antiviral activity .

HY-10300

Narlaprevir 4 Publications Verification SCH 900518	HCV HCV Protease SARS-CoV	Infection
Narlaprevir (SCH 900518) is a selective and orally bioavailable NS3 protease inhibitor with a K_i value of 6 nM and an EC₉₀ value of 40 nM . Narlaprevir also inhibits the HCV nonstructural protein 3 serine protease . Narlaprevir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.3 μM ^[3].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-17367

Atazanavir Maximum Cited Publications 11 Publications Verification BMS-232632	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of *CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)* . Atazanavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM ^[3].

HY-17367A

Atazanavir sulfate Maximum Cited Publications 11 Publications Verification BMS-232632 sulfate	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (BMS-232632) sulfate, a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir sulfate is a substrate and inhibitor of *CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)* . Atazanavir sulfate is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 3.49 μM ^[3].

HY-N0063

Punicalagin 5 Publications Verification	Infection Structural Classification Punica granatum L. Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Punicaceae Plants Disease Research Fields	SARS-CoV HBV
Punicalagin is a polyphenol ingredient isolated from Pomegranate (Punica granatum L.) or the leaves of Terminalia catappa L.. Punicalagin is a reversible and non-competitive *3CL ^pro* inhibitor and inhibits SARS-CoV-2 replication in vitro. Punicalagin is an anti-hepatitis B virus (HBV) agent and has antioxidant, anti-inflammatory, and anticancer effects. Punicalagin has the potential for the research of COVID-19 ^[3].

HY-N12384

(25S)-Antcin B	Triterpenes Structural Classification Microorganisms Terpenoids Source classification	SARS-CoV
Antcin-B is a potent inhibitor of *3CLPro* with high affinity. Antcin-B can be used in study SARS-CoV-2 .

HY-N8306

Isojacareubin	Structural Classification Flavonoids Flavones Source classification Guttiferae Plants Hypericum japonicum Thunb. ex Murray	Bacterial PKC Apoptosis SARS-CoV
Isojacareubin can be isolated from Hypericum japonicum. Isojacareubin covalently inhibits SARS-CoV-2 3CLpro. Isojacareubin also has anti-helicobacter activity. Isojacareubin inhibits PKC, and suppresses hepatocellular carcinoma metastasis and induces apoptosis ^[3].

Cat. No.	Product Name	Chemical Structure

HY-90001S

Ritonavir-d6
Ritonavir-d₆ is the deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM[1][2].

HY-90001S2

Ritonavir-d8
Ritonavir-d₈ is deuterated labeled Ritonavir (HY-90001). Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.61 μM.

HY-17007S

Saquinavir-d9
Saquinavir-d₉ is the deuterium labeled Saquinavir. Saquinavir(Ro 31-8959) is an HIV Protease inhibitor used in antiretroviral therapy. Saquinavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.36 μM[1][2].

HY-90001S1

Ritonavir-13C,d3
Ritonavir- ¹³C,d₃ is the ¹³C- and deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM.

HY-17430S1

Amprenavir-d4-1
Amprenavir-d₄-1 is deuterium labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM.

HY-17430S

Amprenavir-d4
Amprenavir-d₄ is the deuterium labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM[1][2].

HY-15148S1

Tipranavir-d7
Tipranavir-d₇ is deuterated labeled Tipranavir (HY-15148). Tipranavir (PNU-140690) inhibits the enzymatic activity and dimerization of HIV-1 protease, exerts potent activity against multi-protease inhibitor (PI)-resistant HIV-1 isolates with IC₅₀s of 66-410 nM . Tipranavir inhibits SARS-CoV-2 3CL ^pro activity ^[3].

HY-15602S

Ledipasvir-d6
Ledipasvir-d₆ is the deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.62 μM[3].

HY-90001S3

rel-Ritonavir-d6
rel-Ritonavir-d₆ (rel-ABT 538-d₆; rel-RTV-d₆) is the deuterium labeled Ritonavir (HY-90001). Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 1.61 μM .

HY-14588S2

Lopinavir-d7

Lopinavir-d₇ is deuterated labeled Lopinavir (HY-14588). Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 14.2 μM ^[3].

HY-10237S

Boceprevir-d9
Boceprevir-d₉ is the deuterium labeled Boceprevir. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a Ki of 14 nM in both enzyme assay and an EC90 of 350 nM in cell-based replicon assay[1][2][3][4][5]. Boceprevir inhibits SARS-CoV-2 3CLpro activity[6].

HY-17367S3

Atazanavir-d5
Atazanavir-d₅ is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-17367S2

Atazanavir-d9
Atazanavir-d₉ is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-10235S

Telaprevir-d4
Telaprevir-d₄ is the deuterium labeled Telaprevir. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide[1][2][3]. Telaprevir inhibits SARS-CoV-2 3CLpro activity[4].

HY-17367S4

Atazanavir-d6
Atazanavir-d₆ is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].

HY-14588S

(rel)-Lopinavir-d8

(rel)-Lopinavir-d₈ ((rel)-ABT-378-d₈)is the deuterium labeledLopinavir(HY-14588) . Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity ^[3]. Lopinavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 14.2 μM .

HY-14588S1

Lopinavir-d8
Lopinavir-d₈ (ABT-378-d8) is the deuterium labeled Lopinavir. Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with Kis of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity[1][2]. Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 14.2 μM[3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks